CD276 and neoplasm: While monotherapy approaches targeting B7-H3 often face restrictions due to tumor heterogeneity, immune evasion, and a suppressive tumor immune microenvironment, recent efforts have increasingly focused on combining B7-H3 directed modalities with other molecular or immune interventions to improve tumor selectivity, durability, and efficacy.